阿立哌唑
利培酮
心理学
易怒
自闭症
随机对照试验
不利影响
精神科
临床试验
儿科
医学
内科学
精神分裂症(面向对象编程)
焦虑
作者
Ahmad Ghanizadeh,Aliakbar Sahraeizadeh,Michael Berk
标识
DOI:10.1007/s10578-013-0390-x
摘要
Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI